Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748695 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury
A Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01748695: Completed Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury, sponsored by Brigham and Women's Hospital.
NCT01748695 is a Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01748695, a Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether V158866 is safe and effective for the treatment of neuropathic pain due to spinal cord injury.
Primary Outcome
Numerical Rating Scale, measuring the intensity of pain from 0 to 10, with 0 being no pain and 10 being worst pain imaginable. The comparison of the overall pain intensity, calculated as the mean of the last 7 days on treatment, for each treatment period (V158866 compared to placebo).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG V158866
Study Locations (1)
Massachusetts
- Translational Pain Research, Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT01748695 record still lists
NCT01748695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Neuropathic Pain Due to Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01748695 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01748695 about?
NCT01748695 is a clinical study titled "A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury". The purpose of this study is to investigate whether V158866 is safe and effective for the treatment of neuropathic pain due to spinal cord injury.
What is the current status of trial NCT01748695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-06. Estimated completion is 2015-07.
What conditions does trial NCT01748695 study?
This clinical trial studies the following conditions: Neuropathic Pain Due to Spinal Cord Injury.
What interventions are being tested in trial NCT01748695?
The interventions under investigation include: Placebo (DRUG), V158866 (DRUG).
Who is sponsoring clinical trial NCT01748695?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01748695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01748695's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia